<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04879407</url>
  </required_header>
  <id_info>
    <org_study_id>DUPLICATE-EINSTEIN-PE</org_study_id>
    <nct_id>NCT04879407</nct_id>
  </id_info>
  <brief_title>Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data</brief_title>
  <official_title>Replication of the EINSTEIN-PE Anticoagulant Trial in Healthcare Claims Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators are building an empirical evidence base for real world data through large-scale&#xD;
      replication of randomized controlled trials. The investigators' goal is to understand for&#xD;
      what types of clinical questions real world data analyses can be conducted with confidence&#xD;
      and how to implement such studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE&#xD;
      initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical&#xD;
      School. It is intended to replicate, as closely as possible in healthcare insurance claims&#xD;
      data, the trial listed below/above. Although many features of the trial cannot be directly&#xD;
      replicated in healthcare claims, key design features, including outcomes, exposures, and&#xD;
      inclusion/exclusion criteria, were selected to proxy those features from the trial.&#xD;
      Randomization is also not replicable in healthcare claims data but was proxied through a&#xD;
      statistical balancing of measured covariates through standard practice. Investigators assume&#xD;
      that the RCT provides the reference standard treatment effect estimate and that failure to&#xD;
      replicate RCT findings is indicative of the inadequacy of the healthcare claims data for&#xD;
      replication for a range of possible reasons and does not provide information on the validity&#xD;
      of the original RCT finding.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 10, 2020</start_date>
  <completion_date type="Anticipated">June 11, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 11, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relative hazard of recurrent venous thromboembolic events</measure>
    <time_frame>Through study completion or censoring, up to 12 months</time_frame>
    <description>Claims-based algorithm: see attached protocol for full definition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative hazard of major bleeding</measure>
    <time_frame>Through study completion or censoring, up to 12 months</time_frame>
    <description>Claims-based algorithm: see attached protocol for full definition</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">98947</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <description>Reference group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <description>Exposure group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Any rivaroxaban dispensing claim is used as the exposure group</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Any warfarin dispensing claim is used as the reference group</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will involve a new user, parallel group, propensity score-matched, retrospective&#xD;
        cohort study design comparing rivaroxaban to warfarin users. The patients will be required&#xD;
        to have continuous enrollment during a baseline period of 180 days before initiation of&#xD;
        rivaroxaban or warfarin (index date). We will restrict the analyses to patients with a&#xD;
        diagnosis of acute symptomatic proximal PE with or without symptomatic DVT.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Criteria:&#xD;
&#xD;
        Please see https://drive.google.com/drive/folders/1WD618wrywYjEaXzfLTcuK-VCcnb6b-gV for&#xD;
        full code and algorithm definitions.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed acute symptomatic proximal PE with or without symptomatic DVT&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Legal lower age limitations [Day 0, Day 0]&#xD;
&#xD;
          -  Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the&#xD;
             current episode of DVT or PE [Day -14, Day 0]&#xD;
&#xD;
          -  Other indications for VKA than DVT and/or PE [Day -180, Day 0]&#xD;
&#xD;
          -  Creatinine clearance &lt;30 ml/min [Day -180, Day 0]&#xD;
&#xD;
          -  Significant liver disease (e.g. acute hepatitis, chronic active hepatitis, cirrhosis)&#xD;
             or ALAT&gt;3x ULN [Day -180, Day 0]&#xD;
&#xD;
          -  Bacterial endocarditis [Day -180, Day 0]&#xD;
&#xD;
          -  Life expectancy &lt;3 months [Day -365, Day 0]&#xD;
&#xD;
          -  Active bleeding or high risk for bleeding contraindicating treatment with enoxaparin&#xD;
             or VKA [Day -180, Day 0]&#xD;
&#xD;
          -  Systolic blood pressure &gt;180 mgHg or diastolic blood pressure &gt;110mgHg [Day -180, Day&#xD;
             0]&#xD;
&#xD;
          -  Childbearing potential without proper contraceptive measures, pregnancy or&#xD;
             breastfeeding [Day -180, Day 0]&#xD;
&#xD;
          -  Concomitant use of strong CYP3A4 inhibitors (e.g. HIV protease inhibitors, systemic&#xD;
             ketoconazole) or strong CYP3A4 inducers rifampin [Day -14, Day 0]&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Franklin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shirley Wang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Jessica Franklin</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 3, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT04879407/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

